PHAXIAM Therapeutics S.A.

As of December 31, 2022, PHAXIAM Therapeutics S.A. has 3.36M shares outstanding.

These figures are as of December 31, 2022.

These figures are as of December 31, 2022. PHAXIAM Therapeutics S.A. trades at an EV/FCF ratio of 270.18, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2022, PHAXIAM Therapeutics S.A. maintains a current ratio of 3.65, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.77, indicating elevated leverage, while an interest coverage ratio of -85.10 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2022. Return on invested capital (ROIC) comes in at 49.55 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -0.41, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 10.73, useful for judging operating efficiency across full business cycles.

These figures cover the twelve months ended December 31, 2022. That works out to an effective tax rate of 177.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

PHAXIAM Therapeutics S.A.'s most recent stock split took place on June 13, 2024 with a 61:66 split ratio.

As of December 31, 2022, PHAXIAM Therapeutics S.A. has an Altman Z-Score of -0.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.